Disease · MONDO_0004952
Comparisons in its trials92
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 92
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values | 662 of 662 | 658 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| A+AVD vs ABVD: deaths from any cause | 9 of 662 | 13 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| A+AVD vs ABVD: serious adverse events | 284 of 662 | 178 of 659 | 1,321 | NCT01712490 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Overall Survival | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Event-free Survival (EFS) | 52 of 487 | 91 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Progression Free Survival (PFS) | 41 of 487 | 81 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): deaths from any cause | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): serious adverse events | 140 of 481 | 18 of 476 | 957 | NCT03907488 | Trial comparisons |
| Arm A (ABVD) vs Arm B (Stanford V): serious adverse events | 355 of 414 | 401 of 422 | 836 | NCT00003389 | Trial comparisons |
| Arm A (ABVD) vs Arm B (Stanford V): Incidence of Second Cancers | 15 of 395 | 19 of 399 | 794 | NCT00003389 | Trial comparisons |
| Brentuximab Vedotin vs Placebo: deaths from any cause | 45 of 167 | 40 of 160 | 327 | NCT01100502 | Trial comparisons |
| Brentuximab Vedotin vs Placebo: serious adverse events | 43 of 167 | 21 of 160 | 327 | NCT01100502 | Trial comparisons |
| Phase I (Panobinostat + Everolimus) vs Phase II (Panobinostat + Everolimus): deaths from any cause | 0 of 23 | 1 of 93 | 116 | NCT00918333 | Trial comparisons |
| Phase I (Panobinostat + Everolimus) vs Phase II (Panobinostat + Everolimus): serious adverse events | 3 of 23 | 25 of 93 | 116 | NCT00918333 | Trial comparisons |
| BV Extension vs BV Retreatment: serious adverse events | 16 of 78 | 9 of 32 | 110 | NCT00947856 | Trial comparisons |
| BeEAM vs BEAM: deaths from any cause | 4 of 53 | 6 of 55 | 108 | NCT02278796 | Trial comparisons |
| BeEAM vs BEAM: serious adverse events | 6 of 53 | 6 of 55 | 108 | NCT02278796 | Trial comparisons |
| Un-Manipulated CB Arm vs Expanded CB Arm: Number of Participants With Engraftment | 45 of 52 | 44 of 53 | 105 | NCT00067002 | Trial comparisons |
| Un-Manipulated CB Arm vs Expanded CB Arm: serious adverse events | 9 of 52 | 4 of 53 | 105 | NCT00067002 | Trial comparisons |
| BeEAM vs BEAM: Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at Least 20%. | 8 of 51 | 11 of 52 | 103 | NCT02278796 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004952/comparisons